IP Verse

Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated Disorders

Patent No. EP3310760 (titled "Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated Disorders") was filed by Arena Pharmaceuticals on Jun 21, 2016. The application was issued on Oct 19, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
SANDOZJun 14, 2023KRAUS & LEDERER PARTGMBB
SCORPIOJun 14, 2023SAGITTARIUS

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3310760

ARENA PHARMACEUTICALS
Application Number
EP16734529A
Filing Date
Jun 21, 2016
Status
Granted And Under Opposition
Aug 12, 2022
Publication Date
Oct 19, 2022
External Links
Slate, Register , Google Patents